Interleukin-6 predicts recurrence and survival among head and neck cancer patients
Interleukin-6 predicts recurrence and survival among head and neck cancer patients
复制标题
DOI：
10.1002/cncr.23615
复制
发表时间：
2008-08-15
期刊：
影响因子：
6.2
通讯作者：
Teknos, Theodoros N.
中科院分区：
文献类型：
--
作者：
Duffy, Sonia A.;Taylor, Jeremy M. G.;Teknos, Theodoros N.
背景头颈部鳞状细胞癌（HNSCC）患者治疗前血清白细胞介素（IL）-6水平升高与预后不良相关，但先前研究的样本量较小，因此无法控制其他已知的预后变量。一项纵向前瞻性队列研究确定了治疗前血清IL-6水平与既往未经治疗的HNSCC患者的大人群（N = 444）中肿瘤复发和全因生存率之间的相关性。控制变量包括年龄、性别、吸烟、癌症部位和分期以及合并症。使用Kaplan-Meier图以及单变量和多变量考克斯比例风险模型来研究IL-6水平、控制变量与复发时间和生存率之间的相关性。结果。中位血清IL-6水平为13 pg/mL（范围，0-453）。2年复发率为35.2%（标准误为2.67%）。2年死亡率为26.5%（标准误为2.26%）。多变量分析显示，血清IL-6水平独立预测复发，风险比（HR）为1.32; 95%可信区间（CI）为1.11 - 1.58; P = 0.0021，癌症部位（口腔/鼻窦）也是如此。血清IL-6水平也是生存率差的一个重要的独立预测因子（HR = 1.22; 95%CI，1.02 - 1.46; P = 0.03），与年龄、吸烟、癌症部位（口腔/鼻窦）、较高的癌症分期和合并症一样。治疗前血清IL-6可能是预测HNSCC患者复发和总生存的有价值的生物标志物。使用IL-6作为复发和存活的生物标志物可以允许更早地识别和治疗疾病复发。
BACKGROUND. increased pretreatment serum interleukin (IL)-6 levels among patients with head and neck squamous cell carcinoma (HNSCC) have been shown to correlate with poor prognosis, but sample sizes in prior Studies have been small and thus unable to control for other known prognostic variables.METHODS. A longitudinal, prospective cohort study determined the correlation between pretreatment serum IL-6 levels, and tumor recurrence and all-cause survival in a large population (N = 444) of previously untreated HNSCC patients. Control variables included age, sex, smoking, cancer site and stage, and comorbidities. Kaplan-Meier plots and univariate and multivariate Cox proportional hazards models were used to study the association between IL-6 levels, control variables, and time to recurrence and survival.RESULTS. The median serum IL-6 level was 13 pg/mL (range, 0-453). The 2-year recurrence rate was 35.2% (standard error, 2.67%). The 2-year death rate was 26.5% (standard error, 2.26%). Multivariate analyses showed that serum IL-6 levels independently predicted recurrence at significant levels [hazard ratio (HR) 1.32; 95% confidence interval (CI), 1.11 to 1.58; P = .0021 as did cancer site (oral/sinus). Serum IL-6 level was also a significant independent predictor of poor survival (HR = 1.22; 95% CI, 1.02 to 1.46; P = .03), as were older age, smoking, cancer site (oral/sinus), higher cancer stage, and comorbidities.CONCLUSIONS. Pretreatment serum IL-6 could be a valuable biomarker for predicting recurrence and overall survival among HNSCC patients. Using IL-6 as a biomarker for recurrence and Survival may allow for earlier identification and treatment of disease relapse.